Premium
Acute confusional state after designer tryptamine abuse
Author(s) -
ITOKAWA MASANARI,
IWATA KEN,
TAKAHASHI MISAKO,
SUGIHARA GENICHI,
SASAKI TAKESHI,
ABE YUICHIRO,
UNO MINARI,
HOBO MIZUE,
JITOKU DAISUKE,
INOUE KIKUE,
ARAI MAKOTO,
YASUDA ICHIRO,
SHINTANI MASAHIRO
Publication year - 2007
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.2007.01638.x
Subject(s) - tryptamine , urinalysis , designer drug , glasgow coma scale , presentation (obstetrics) , coma (optics) , urine , chromatography , chemistry , medical emergency , medicine , emergency medicine , anesthesia , psychiatry , pharmacology , surgery , drug , physics , optics
A 23‐year‐old Japanese woman was brought to the emergency department about 6.5 h after taking liquid and later a half tablet purchased on the street. About 4.5 h prior to presentation, she displayed excited and disorganized behavior. On examination, she was not alert or oriented, with a Glasgow Coma Scale score of 13, did not answer any questions from doctors while smirking and looking around restlessly, and sometimes exhibited echolalia, imitating the speech of doctors. She was given intravenous infusion of fluid for 8 h, then discharged. Gas chromatography‐mass spectrometry of urine revealed 5‐methoxy‐diisopropyltryptamine, 5‐methoxy‐N‐methyltryptamine and an unidentified tryptamine. Identifying chemical products based solely on information of users is insufficient, and urinalysis is necessary in cases potentially involving designer drugs.